HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety in France?

被引：0
|
作者：
Ativon, F. [1 ]
Lebeller, C. [2 ]
Schiestel, T. [3 ]
Grandvuillemin, A. [4 ]
Davani, S. [1 ]
Valnet-Rabier, M. B. [1 ]
机构：
[1] Ctr Reg Pharmacovigilance Franche Comte, Besancon, France
[2] Ctr Reg Pharmacovigilance Paris, HEGP, Paris, France
[3] Ctr Reg Pharmacovigilance Paris Fernand Widal, Paris, France
[4] Ctr Reg Pharmacovigilance Bourgogne, Dijon, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2021年 / 35卷
关键词：
HIV PrEP; TDF/emtricitabine; safety;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-117
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [21] Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women
    Mugwanya, Kenneth
    Baeten, Jared
    Celum, Connie
    Donnell, Deborah
    Nickolas, Thomas
    Mugo, Nelly
    Branch, Andrea
    Tappero, Jordan
    Kiarie, James
    Ronald, Allan
    Yin, Michael
    Wyatt, Christina
    JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (07): : 1050 - 1057
  • [22] Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine
    Dumond, Julie B.
    Bay, Camden P.
    Nelson, Julie A. E.
    Davalos, Angel
    Edmonds, Andrew
    De Paris, Kristina
    Sykes, Craig
    Anastos, Kathryn
    Sharma, Roopali
    Kassaye, Seble
    Tamraz, Bani
    French, Audrey L.
    Gange, Stephen
    Ofotokun, Ighovwerha
    Fischl, Margaret A.
    Vance, David E.
    Adimora, Adaora A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (09)
  • [23] Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis
    Taneva, Ekaterina
    Crooker, Kerry
    Park, Sung Hyun
    Su, Jonathan T.
    Ott, Adina
    Cheshenko, Natalia
    Szleifer, Igal
    Kiser, Patrick F.
    Frank, Bruce
    Mesquita, Pedro M. M.
    Herold, Betsy C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (03) : 1667 - 1675
  • [24] Preexposure prophylaxis failure with tenofovir disoproxil
    Esser, Stefan
    Streeck, Hendrik
    AIDS, 2017, 31 (09) : 1344 - 1344
  • [25] Emtricitabine/rilpivirine/tenofovir disoproxil fumarate/emtricitabine/tenofovir disoproxil fumarateCluster headache: 2 case reports
    Reactions Weekly, 2019, 1767 (1) : 134 - 134
  • [26] Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring
    Koss, Catherine A.
    Liu, Albert Y.
    Castillo-Mancilla, Jose
    Bacchetti, Peter
    McHugh, Cricket
    Kuncze, Karen
    Morrow, Mary
    Louie, Alexander
    Seifert, Sharon
    Okochi, Hideaki
    MaWhinney, Samantha
    Gandhi, Monica
    Anderson, Peter L.
    AIDS, 2018, 32 (15) : 2189 - 2194
  • [27] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Greg L. Plosker
    Drugs, 2013, 73 : 279 - 291
  • [28] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Plosker, Greg L.
    DRUGS, 2013, 73 (03) : 279 - 291
  • [29] LC Assay for a HIV Tablet Containing Emtricitabine, Tenofovir Disoproxil Fumarate and Rilpivirine
    Pendela, Murali
    Kahsay, Getu Weldu
    Van den Mooter, Guy
    Baert, Lieven
    Hoogmartens, Jos
    Adams, Erwin
    CHROMATOGRAPHIA, 2011, 73 (5-6) : 439 - 445
  • [30] Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough?
    Krakower, Douglas S.
    Mayer, Kenneth H.
    JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (07): : 983 - 985
12345